Urigen Pharmaceuticals has established a partnerships with Hyaluron Contract Manufacturing (HCM) to develop URG101, Urigen’s proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome (PBS).   “Urigen’s development program with Hyaluron is a critical step forward for URG101,” commented William J. Garner, M.D., president and chief executive officer of Urigen. “Hyaluron, with its quality-focused and innovative drug development team, ...